Brian Leyland-Jones

Summary

Affiliation: Emory University
Country: USA

Publications

  1. pmc Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform
    M Abramovitz
    VM Institute of Research, 2020 University Street, Montreal, Quebec H3A 2A5, Canada
    Br J Cancer 105:1574-81. 2011
  2. pmc Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts
    B G Barwick
    Emory Biomarker Service Center, Emory University, 1365C Clifton Road, NE, Atlanta, GA 30322, USA
    Br J Cancer 102:570-6. 2010
  3. doi request reprint Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
    Brian Leyland-Jones
    Emory Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Lancet Oncol 12:286-95. 2011
  4. doi request reprint Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University, School of Medicine, 1365C Clifton Rd NE, Ste 4014, Atlanta, GA 30322, USA
    J Clin Oncol 28:960-6. 2010
  5. doi request reprint Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA
    J Clin Oncol 27:5278-86. 2009
  6. pmc Recommendations for collection and handling of specimens from group breast cancer clinical trials
    Brian R Leyland-Jones
    Emory University School of Medicine, Atlanta, GA 30322, USA
    J Clin Oncol 26:5638-44. 2008
  7. doi request reprint Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models
    Nezha Alami
    Oncology Department, McGill University, Montreal, QC, Canada
    Growth Horm IGF Res 18:487-96. 2008
  8. pmc Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay
    Mark Abramovitz
    VM Institute of Research, Montreal, Quebec, Canada
    Biotechniques 44:417-23. 2008
  9. ncbi request reprint Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
    Lori Jerome
    Department of Oncology, McGill University, West, Montreal, Quebec, Canada
    Cancer Res 66:7245-52. 2006
  10. ncbi request reprint Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment
    Mark Abramovitz
    VM Institute of Research, Montreal, Quebec, Canada
    Cancer Genomics Proteomics 4:135-45. 2007

Collaborators

Detail Information

Publications20

  1. pmc Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform
    M Abramovitz
    VM Institute of Research, 2020 University Street, Montreal, Quebec H3A 2A5, Canada
    Br J Cancer 105:1574-81. 2011
    ..In order to extend the utility of the DASL assay for breast cancer, we have custom designed and validated a 512-gene human breast cancer panel...
  2. pmc Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts
    B G Barwick
    Emory Biomarker Service Center, Emory University, 1365C Clifton Road, NE, Atlanta, GA 30322, USA
    Br J Cancer 102:570-6. 2010
    ..To identify markers associated with TMPRSS2-ERG fusion and prognostic of biochemical recurrence, we analysed a cohort of 139 men with prostate cancer for 502 molecular markers...
  3. doi request reprint Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
    Brian Leyland-Jones
    Emory Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Lancet Oncol 12:286-95. 2011
    ..Furthermore, oncologists should continue to use clinical parameters when making decisions about initiation, continuation, and discontinuation of HER2-targeted treatments...
  4. doi request reprint Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University, School of Medicine, 1365C Clifton Rd NE, Ste 4014, Atlanta, GA 30322, USA
    J Clin Oncol 28:960-6. 2010
    ..7 months (in all patients). CONCLUSION An intensive loading regimen of trastuzumab achieved higher-than-steady-state serum concentrations during cycle 1, was well tolerated, and had a good efficacy profile...
  5. doi request reprint Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA
    J Clin Oncol 27:5278-86. 2009
    ..To determine the incidence, outcomes, and current strategies for management of brain metastases in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer...
  6. pmc Recommendations for collection and handling of specimens from group breast cancer clinical trials
    Brian R Leyland-Jones
    Emory University School of Medicine, Atlanta, GA 30322, USA
    J Clin Oncol 26:5638-44. 2008
    ..Recommendations for proper handling and shipping were developed for blood, serum, plasma, FFPE, and fresh/frozen tissue...
  7. doi request reprint Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models
    Nezha Alami
    Oncology Department, McGill University, Montreal, QC, Canada
    Growth Horm IGF Res 18:487-96. 2008
    ..The effects of the different treatments on IGF-IR signaling pathways were also examined...
  8. pmc Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay
    Mark Abramovitz
    VM Institute of Research, Montreal, Quebec, Canada
    Biotechniques 44:417-23. 2008
    ....
  9. ncbi request reprint Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
    Lori Jerome
    Department of Oncology, McGill University, West, Montreal, Quebec, Canada
    Cancer Res 66:7245-52. 2006
    ..These results emphasize the merit of evaluating simultaneous blockade of the HER-2 and IGF-IR pathways using combination therapy with rhIGFBP-3 plus Herceptin in human clinical trials of patients with HER-2-positive breast cancer...
  10. ncbi request reprint Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment
    Mark Abramovitz
    VM Institute of Research, Montreal, Quebec, Canada
    Cancer Genomics Proteomics 4:135-45. 2007
    ..Application of these technologies to our understanding of breast cancer will undoubtedly have an impact on the individualization of treatment for breast cancer patients in the not to distant future...
  11. ncbi request reprint Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    J Clin Oncol 21:3965-71. 2003
    ..This phase II study evaluated the pharmacokinetics and safety of trastuzumab and paclitaxel given every 3 weeks to women with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic breast cancer...
  12. doi request reprint Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
    Mary Jo Lund
    Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, USA
    Breast Cancer Res Treat 113:357-70. 2009
    ..This study examines association of the ER/PR/HER2 subtypes with race and breast cancer survival...
  13. ncbi request reprint Proteomics: new technologies and clinical applications
    Martin Latterich
    Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada
    Eur J Cancer 44:2737-41. 2008
    ....
  14. ncbi request reprint Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Canada
    Semin Oncol 30:174-84. 2003
    ..The enhanced quality of life seen with erythropoietin treatment may also involve a modulation of hypoxia-induced decrement in cognitive functioning. It appears that epoetin alfa is a useful addition to the treatment of breast cancer...
  15. ncbi request reprint Anti-insulin-like growth factor strategies in breast cancer
    Lori Jerome
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Semin Oncol 31:54-63. 2004
    ....
  16. pmc Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration
    Aaron M Mohs
    Department of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, 101 Woodruff Circle Suite 2007, Atlanta, Georgia 30322, United States, Division of Thoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, United States, Departments of Biomedical Engineering, Oncology and Radiology, Emory University, 101 Woodruff Circle, Suite 2007, Atlanta, Georgia 30322, United States, Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, United States, and Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Drive, UA Whitaker Building 4106, Atlanta, Georgia 30332, United States
    Anal Chem 82:9058-65. 2010
    ..After surgery, the SpectroPen device permits further evaluation of both positive and negative tumor margins around the surgical cavity, raising new possibilities for real-time tumor detection and image-guided surgery. ..
  17. pmc Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots
    Jian Liu
    Department of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, 101 Woodruff Circle Suite 2001, Atlanta, Georgia 30322, USA
    ACS Nano 4:2755-65. 2010
    ..For clinical diagnostic applications, multiplexed QD mapping provides correlated molecular and morphological information that is not available from traditional tissue staining and molecular profiling methods...
  18. ncbi request reprint Treating cancer-related hypercalcemia with gallium nitrate
    Brian Leyland-Jones
    Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec, Canada
    J Support Oncol 2:509-16. 2004
    ..Gallium nitrate is an effective treatment option for moderate-to-severe cancer-related hypercalcemia, a setting in which morbidity and mortality are high...
  19. ncbi request reprint Breast cancer trial with erythropoietin terminated unexpectedly
    Brian Leyland-Jones
    McGill University, Montreal, Canada
    Lancet Oncol 4:459-60. 2003